A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas

Clinical trial NCT05113069 · UNKNOWN

Trial details

NCT number: NCT05113069
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

B Cell Lymphoma

Start date: 2021-12-22
Primary completion: 2024-03-31
Enrollment: 170

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.